The cystoscopy and ureteroscopy market is anticipated to grow from US$ 459.11 million in 2024 to US$ 729.30 million by 2031; the market is expected to register a CAGR of 6.9% from 2025 to 2031. The cystoscopy and ureteroscopy market growth are attributed to the increasing prevalence of hearing loss and surging strategic initiatives by market players.

Cystoscopy and ureteroscopy are at the forefront of modern urological care, offering targeted solutions for diagnosing and treating a wide range of urinary tract conditions. These procedures leverage cutting-edge technology through the use of flexible and rigid scopes equipped with high-definition cameras and illumination systems, allowing clinicians to achieve unparalleled visualization of the bladder and urethra.

The cystoscopy and ureteroscopy market in North America is segmented into the US, Canada, and Mexico. The North America cystoscopy and ureteroscopy market is expanding owing to several factors. The US holds the largest market share, followed by Canada. The demand for cystoscopy and ureteroscopy in the region is fueled by the increasing incidence of kidney stones (urolithiasis), bladder cancer, and urinary tract infections.

Advanced technologies, such as Blue Light Cystoscopy, enhance the visualization of bladder cancer lesions beyond what traditional white light can provide. Additionally, the integration of laser systems for stone fragmentation during ureteroscopy highlights the shift toward more sophisticated diagnostic and therapeutic options. Robotics and wireless connectivity offer improved precision, ergonomics, and the capacity for remote diagnostics. Leading medical device manufacturers such as Olympus, KARL STORZ, Boston Scientific, and FUJIFILM spur continuous R&D and strategic collaborations to accelerate product launches and market penetration.

In North America, the US holds a significant share of the cystoscopy and ureteroscopy market. The US dominated the North America cystoscopy and ureteroscopy market in 2024. According to the Department of Urology (University of Florida Health), kidney stones impact 1 in 500 individuals in the US each year. Approximately 1 in 8 men and 1 in 16 women usually develop this condition during their lifetime. The increasing prevalence of kidney stones boosts the demand for cystoscopy and ureteroscopy for early diagnosis and treatment.

According to the National Library of Medicine, UTIs are the most common outpatient infections in the US. The occurrence of UTIs generally increases with age. About 20% of women over 65 experience UTIs, compared to approximately 11% in the overall population. Nearly 50-60% of adult women generally suffer from UTIs at least once in their lifetime.

Recent developments in ureteroscopies and cystoscopies in the US were predominantly made on the technology front to enable more minimally invasive, precise, and patient-centered care. Further, robotic cystoscopes are gaining traction in the medical field, with single-use and robotic-assisted systems offering advancements in cystoscopy procedures. In August 2024, PROCEPT BioRobotics Corporation announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. The HYDROS Robotic System is the only AI-powered platform for Aquablation therapy for benign prostatic hyperplasia (BPH). This proven procedure uses real-time ultrasound and cystoscopy in assisting surgeons by providing a detailed view of the prostate, allowing for personalized treatment. With over 400 robotic systems installed, Aquablation therapy has gained remarkable popularity in the US.

The development of flexible ureteroscopes with enhanced imaging capabilities and reduced diameters by prominent industry players-including Karl Storz, Olympus, Stryker, and Richard Wolf-has markedly accelerated growth within the urological device market. These technological advancements offer improved procedural navigation, reduced patient discomfort, and heightened visual clarity during interventions. Olympus obtained regulatory clearance in the United States for its innovative single-use ureteroscope system, RenaFlex, in April 2024. This state-of-the-art solution is designed to provide efficient access to the urinary tract for diagnosing and treating conditions such as kidney stones, utilizing either transurethral or percutaneous techniques.

The rising prevalence of urinary tract disorders, combined with the launch of such advanced medical technologies, continues to fuel the expansion of the cystoscopy and ureteroscopy segment across the US healthcare landscape.

Shift Toward Robotic-Assisted Urological Surgeries to Provide Market Opportunities in Future

Robotic surgery, particularly with the use of the da Vinci surgical system, is gaining popularity in urological procedures due to its precision, minimal invasiveness, and ability to reduce recovery times. Robotic systems offer greater control, enhanced visualization, and improved dexterity for surgeons, which are crucial when performing delicate procedures such as cystoscopy and ureteroscopy. Advanced robotic-assisted systems in hospitals also contribute to the increase in minimally invasive procedures, benefitting patients by lowering discomfort, shortening hospital stays, and accelerating recovery. In August 2024, PROCEPT BioRobotics Corporation announced the clearance of its HYDROS Robotic System. This next-generation platform features FirstAssist AI treatment planning, advanced image guidance, and robotic resection, making it the only AI-powered system for aquablation therapy for benign prostatic hyperplasia (BPH). The procedure combines real-time ultrasound imaging and cystoscopy, offering surgeons a detailed view of the prostate for personalized treatment planning. Robotic surgeries also aid relief for healthcare providers by keeping a check on blood loss, shortening operating times, and mitigating postoperative complications.

In May 2024, the American University of Beirut Medical Center's Division of Urology shared its initial impressions of the ILY robotic system used for flexible ureteroscopy to treat kidney stones. The robot is operated via an ergonomic wireless joystick controller, which resembles controllers from popular gaming systems such as Xbox or PlayStation. The surgical team reported a stone-free rate of 93.55%, with no patients requiring reoperation for the treated stones. Based on these findings, the ILY robotic flexible ureteroscopy is claimed to be safe and effective. In emerging economy such as India, there were nearly 76 fully functional surgical robots and over 500 surgeons trained to carry out robotic surgeries as of 2021. The Asian Institute of Nephrology and Urology (AINU, India) is a world-class hospital specializing in urology. The AINU is renowned for its expertise in robotic surgery, particularly in the field of prostate-related conditions, making it home to the best surgeons trained in robotically aided procedures. As technology becomes more affordable and accessible, smaller hospitals and clinics also show interest in robotic systems. Thus, the increasing adoption of robotic-assisted surgeries is emerging as a key trend in the cystoscopy and ureteroscopy market.

The US Food and Drug Administration, International Agency For Research On Cancer, American Urological Association, European Association of Urology, Urological Association of Asia, Urology Care Foundation are among the primary and secondary sources referred to while preparing the cystoscopy and ureteroscopy market report.